A Post-Marketing Surveillance Study to Evaluate the Safety and Effectiveness of Harvoni Treatment Regimen in Patients With Chronic Hepatitis C Virus (HCV) Infection in Korea
Latest Information Update: 30 Nov 2021
Price :
$35 *
At a glance
- Drugs Ledipasvir/sofosbuvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- Sponsors Gilead Sciences
- 24 Nov 2021 Status changed from recruiting to completed.
- 04 Jun 2021 Planned End Date changed from 1 Oct 2021 to 1 Jan 2022.
- 04 Jun 2021 Planned primary completion date changed from 1 Oct 2021 to 1 Jan 2022.